Pharmaceuticals News and Research

RSS

Information in hospital prescription records can quite easily re-identify patients, says study

A recent study led by Dr. Khaled El Emam, the Canada Research Chair in Electronic Health Information at the CHEO Research Institute, found that the information in hospital prescription records can quite easily re-identify patients.

14 Oct 2009

Harvard researchers unite in fight against antibiotic resistance

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) have awarded $5 million to an interdisciplinary group of Harvard researchers to launch the "Harvard-wide Program on Antibiotic Resistance."

14 Oct 2009

Senate Finance Committee's bipartisan bill is the best blueprint for comprehensive health care reform: PhRMA

"Today's vote represents an important step forward for the millions of Americans who don't have access to high-quality and affordable health care coverage and services. Chairman Baucus has tirelessly shepherded one of the most important pieces of legislation in our lifetime and deserves a lot of credit for reaching out to members on both sides of the aisle.

14 Oct 2009

VIA Pharmaceuticals receives determination letter from NASDAQ Stock Market

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").

14 Oct 2009

TAXIS Pharmaceuticals, Rutgers and UMDNJ to develop and commercialize a novel antimicrobial technology

TAXIS Pharmaceuticals, Inc. (TAXIS), Rutgers, The State University of New Jersey, and the University of Medicine and Dentistry of New Jersey (UMDNJ) have entered into an exclusive licensing agreement for worldwide rights to develop and commercialize a novel antimicrobial technology addressing multidrug-resistant (MDR) bacterial infections.

14 Oct 2009

New diagnostic technology to detect breast cancer

"We were ready to start a family when a mammogram revealed an abnormal mass in my left breast," said Staci Sansolo, 34, of New Jersey. A biopsy revealed the mass was not cancer, but a second-round test found another area of concern.

14 Oct 2009

Cequent Pharmaceuticals to provide details of its clinical program at BIOCOM conference

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Chief Executive Officer, Peter Parker, will provide details on Cequent's planned launch of its clinical program and highlight strategy and development goals in a company update scheduled for 3 p.m. on Tuesday, October 27, 2009, at the 2009 BIOCOM Investor Conference.

14 Oct 2009

FDA recommends approval for UI Pharmaceuticals to manufacture an aseptically filled sterile drug product

In September 2009, the Kansas City District Office of the Food and Drug Administration (FDA) submitted a recommendation of approval to the Center for Drug Evaluation and Research for The University of Iowa Pharmaceuticals (UIP) to manufacture and test an aseptically filled, sterile prescription drug product for a commercial client. The drug product contains a new chemical entity and is a sterile solution that is aseptically filled into vials.

14 Oct 2009

Sosei Group assigns its SD281 drug discovery programme to Biocopea

Sosei Group Corporation, a biopharmaceutical company, today announces the assignment of the drug discovery programme, SD281 and its analogues, to Biocopea Limited, a UK biotechnology company and subsidiary of PepTcell Limited. These compounds, based on a metabolite of a well-known drug, were shown by Sosei to have pronounced anti-inflammatory properties.

14 Oct 2009

Champions Biotechnology receives U.S. patent for its tubulin inhibitors

Champions Biotechnology, Inc., a drug development company with a preclinical platform able to predict clinical effectiveness, accelerate development and enhance the value of oncology drugs, today announced that the United States Patent and Trademark Office issued a patent on September 29, 2009 for the company's tubulin inhibitors, including its lead compound SG410.

14 Oct 2009

Shire settles pending ADDERALL XR litigation with Sandoz

Shire plc, the global specialty biopharmaceutical company, announces that it has settled all pending litigation with Sandoz, Inc. ("Sandoz") in connection with Sandoz's Abbreviated New Drug Application ("ANDA") and its attempt to market generic versions of Shire's ADDERALL XR(R) (mixed amphetamine salts) for the treatment of Attention Deficit Hyperactivity Disorder.

14 Oct 2009

Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG

Vanda Pharmaceuticals Inc. announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda's anti-psychotic, in the U.S. and Canada. Fanapt(TM) was approved by the U.S. Food and Drug Administration on May 6, 2009 for the acute treatment of schizophrenia in adults.

14 Oct 2009

Decision Resources: Rheumatoid arthritis drug market in India to grow up to $672 million in 2013

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market in India will more than double by 2013, growing from $296 million in 2008 to $672 million in 2013.

14 Oct 2009

Ahura Scientific expands global customer base in China and Germany

Ahura Scientific, Inc., the leader in field-deployed analytical instruments for human health and public safety, today announced an upgrade to the language capabilities of TruScan, its handheld Raman spectrometer designed for the stringent requirements of the pharmaceutical and consumer health industries.

14 Oct 2009

Positive results from Metabolex' Phase 1 MBX-2982 clinical trial for treating type 2 diabetes

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from two multiple ascending dose Phase 1 clinical trials of MBX-2982.

14 Oct 2009

Also in Global Health News: Ban addresses women's health; Afghanistan's health services; PMI Africa grants; Q&As

U.N. Secretary-General Ban Ki-Moon on Monday called for countries around the world to "renew their commitment to educate girls, end sexual violence, and provide access to modern birth control," the Associated Press/Washington Post reports.

14 Oct 2009

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

AVANIR Pharmaceuticals, Inc. today announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).

14 Oct 2009

African leaders, Chirac unite to fight fake drug manufacturing, distribution

Leaders from Benin, Burkina Faso, the Central African Republic, Congo-Republic, Niger and Senegal on Monday joined former French President Jacques Chirac in Cotonou, Benin, in a campaign against the manufacturing and sale of fake pharmaceutical products, Reuters reports (Lewis, 10/12).

14 Oct 2009

Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain

Meda Pharmaceuticals Inc. today announced the launch of Onsolis(TM)(fentanyl buccal soluble film) in the U.S. for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

13 Oct 2009

Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121

Dyax Corp. announced today new developments involving drug candidates identified using the Company’s proprietary phage display technology as a result of two deals recently announced by sanofi-aventis.

13 Oct 2009

Pharmaceuticals News and Research

Information in hospital prescription records can quite easily re-identify patients, says study

Harvard researchers unite in fight against antibiotic resistance

Senate Finance Committee's bipartisan bill is the best blueprint for comprehensive health care reform: PhRMA

VIA Pharmaceuticals receives determination letter from NASDAQ Stock Market

TAXIS Pharmaceuticals, Rutgers and UMDNJ to develop and commercialize a novel antimicrobial technology

New diagnostic technology to detect breast cancer

Cequent Pharmaceuticals to provide details of its clinical program at BIOCOM conference

FDA recommends approval for UI Pharmaceuticals to manufacture an aseptically filled sterile drug product

Sosei Group assigns its SD281 drug discovery programme to Biocopea

Champions Biotechnology receives U.S. patent for its tubulin inhibitors

Shire settles pending ADDERALL XR litigation with Sandoz

Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG

Decision Resources: Rheumatoid arthritis drug market in India to grow up to $672 million in 2013

Ahura Scientific expands global customer base in China and Germany

Positive results from Metabolex' Phase 1 MBX-2982 clinical trial for treating type 2 diabetes

Also in Global Health News: Ban addresses women's health; Afghanistan's health services; PMI Africa grants; Q&As

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

African leaders, Chirac unite to fight fake drug manufacturing, distribution

Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain

Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring